Related Experiment Videos
Randomized controlled trials to assess therapies for multiple sclerosis
Dean M Wingerchuk1, John H Noseworthy
1Department of Neurology, Mayo Clinic and Mayo Foundation, Scottsdale, AZ 55905, USA.
Abstract:
MS poses formidable challenges to clinical investigators. Obstacles to the study of MS therapies include disease chronicity, an unpredictable clinical course, radiologic and pathologic heterogeneity, and limited understanding of the underlying pathophysiology. Randomized controlled trials (RCTs) provide a means to assess therapeutic efficacy while reducing the risks of study bias and confounding factors that influence interpretation of results. RCTs have demonstrated that type 1 interferons and glatiramer acetate alter the short-term natural history of MS and have served as the basis of approval for the marketing of these treatments. Improvements and optimization of trial methodology may hasten the discovery of effective therapies and facilitate better comparisons of the results of individual drug trials. The most urgent need is for improved surrogate end points for clinical outcome with predictive validity for long-term disability. Even if RCT methodology is optimal, however, several limitations inherent to MS trials threaten to impede further progress, including obstacles to long-term studies (e.g., costs), patient withdrawal, and escalating sample size requirements to detect partial therapeutic benefit. There is a crucial need to develop alternative investigative methods, possibly through enhanced collaboration across centers and with industry, and by exploring innovative techniques to use existing RCT and natural history databases to greater advantage.
Insights
Investigating multiple sclerosis (MS) therapies faces challenges like disease complexity and unpredictable courses. Optimizing clinical trial methods and developing better outcome measures are crucial for faster discovery of effective treatments.
Area of Science:
- Neurology
- Clinical Trials
- Pharmacology
Background:
- Multiple sclerosis (MS) presents significant challenges for clinical research due to its chronic nature, unpredictable progression, and heterogeneity.
- Understanding MS pathophysiology remains limited, complicating the development and testing of new therapies.
Purpose of the Study:
- To review the challenges in conducting clinical trials for multiple sclerosis therapies.
- To highlight the importance of optimizing trial methodologies and surrogate endpoints for future drug development.
Main Methods:
- The study reviews existing literature and methodologies used in randomized controlled trials (RCTs) for MS therapies.
- It discusses limitations of current RCTs and proposes areas for improvement in trial design and data analysis.
Main Results:
- RCTs have successfully demonstrated the efficacy of type 1 interferons and glatiramer acetate in altering the short-term course of MS.
- Key challenges include disease chronicity, heterogeneity, unpredictable course, and limitations in surrogate endpoints for long-term disability.
Conclusions:
- Optimizing MS clinical trial methodology, including the development of predictive surrogate endpoints, is essential to accelerate the discovery of effective therapies.
- Addressing limitations such as cost, patient withdrawal, and sample size requirements through collaboration and innovative data utilization is critical for future progress.